B-Cell Sorting Platform for Native Antibody Discovery ONLINE INQUIRY

Aiming to contribute to discovering and developing next-generation antibody therapies, Creative Biolabs currently has pushed out a high-throughput B cell sorting platform to discover unique antibodies in a short period for our worldwide clients. Our powerful B cell sorting platform can not only screen a large number of B-cells from humans or immunized animals but also identify rare antibodies with the biological activity of interest and favorable manufacturing properties.

Therapeutic Antibody Development

Therapeutic antibodies, especially monoclonal antibodies (mAb), are playing increasingly important roles in prognosis, diagnosis, and therapeutics in various diseases including cancer, autoimmunity, metabolic and infectious diseases. Currently, many technologies have been developed for mAb production, which mainly includes hybridoma technology, transgenic mouse technology, phage display technology, and single B cell cloning technology (Fig. 1).

1. Hybridoma technology is developed to fuse animal splenocytes with myeloma cells to produce persistent antibody-secreting hybridomas. Due to the ability to generate high specific monoclonal antibodies, this traditional technique is still widely used now. There are many of mAb-based therapeutics approved that are originally discovered by the hybridoma method.
2. To reduce the immunogenicity of rodent antibodies as therapeutic agents, the technology of using transgenic animals to develop human antibodies has been explored. By introducing human antibody genes into the mouse (or other animals) germlines, transgenic animals can directly generate high affinity, fully human antibodies.
3. Phage display technology is realized by inserting the antibody DNA sequence into the appropriate position of the coat protein gene of the phage. As the phage expands, the antibody is expressed and displayed on the surface of the phage.
4. Other methods, such as human hybridoma and Epstein-Barr virus immortalized human B cells, can also be used to obtain human monoclonal antibodies.

Fig.1 Approaches for the development of therapeutic antibodies.^{1, 3}

B Cell Sorting Platform

Single B cell antibody technology was explored to generate antibodies with naturally paired heavy chain and light chain, which directly isolate antibody-secreting B cells from the immunized animals, then amplify and express VH and VL region encoding genes in vitro. Creative Biolabs has successfully constructed a comprehensive B cell sorting platform, which is capable of the high-throughput screening and generation of natural mAbs of different species in a short period, allowing us to isolate single antigen-specific plasma cells to retrieve Native™ antibodies with extremely high in vivo specificity and affinity. The workflow of antibody discovery involves animal immunization, isolation of B-cells, cloning of single cells, expression and screening of antibodies. We present a comprehensive platform for antibody development, a series of technologies including hybridoma, phage display, yeast display, single-cell isolation, antibody characterization, etc., to facilitate getting monoclonal antibodies for various applications.

Fig.2 Workflow summary of mAb discovery by B cell sorting.^{2, 3}

Highlights of Our B Cell Sorting Platform

• Available for multiple species.
• Ultra-high-throughput screening and time saving.
• Highly in vivo specificity and affinity.
• Unprecedented single-cell resolution.
• Ideal for important and challenging target antigens.

As a biotechnology company keeping pace with the times, Creative Biolabs is specialized in antibody discovery and development and harbors extensive experience in antibody generation using our comprehensive platform. We leverage the leading single-B-cell functional antibody discovery technology to develop Native™ antibodies. Based on vast experience and solid technical strength, we currently provide comprehensive antibody development services to accelerate therapeutic antibody drug discovery.

References

1. Lu, Ruei-Min, et al. "Development of therapeutic antibodies for the treatment of diseases." Journal of biomedical science 27 (2020): 1-30.
2. Goldstein, Leonard D., et al. "Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies." Communications biology 2.1 (2019): 304.
3. Distributed under Open Access license CC BY 4.0, without modification.

Related Sections:

• Applications
• Species
• Immunization
• Single B Cell Isolation
• B Cell Antibody Gene Amplification
• B Cell Antibody Generation

ONLINE INQUIRY